Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-β-lactamase-producing Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 4006-4008

  Auer, Simon ^a   Wojna, Alexandra ^b   Hell, Markus ^a  

^a University Salzburg   (Austria)

^b Private Laboratories Dr Mustafa/Dr Richter   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; NITROFURANTOIN; PIVMECILLINAM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHILD; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; URINARY TRACT INFECTION;

AMDINOCILLIN PIVOXIL; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; URINARY TRACT INFECTIONS;

EID: 77956128051     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01760-09     Document Type: Article

References (22)

1. Alhambra, A., J. A. Cuadros, J. Cacho, J. L. Gomez-Garces, and J. I. Alos. 2004. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. 53:1090-1094.
2. Bradford, P. A. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
3. Chaudhary, U., and R. Aggarwal. 2004. Extended-spectrum lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian J. Med. Microbiol. 22:75-80.
4. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
5. de Cueto, M., J. R. Hernandez, L. Lopez-Cerero, C. Morillo, and A. Pascual. 2006. Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm. Infecc. Microbiol. Clin. 24:613-616.
6. Estebanez, A., R. Pascual, V. Gil, F. Ortiz, M. Santibanez, and B. C. Perez. 2009. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur. J. Clin. Microbiol. Infect. Dis. 28:1457-1464.
7. Garau, J. 2008. Other antimicrobials of interest in the era of extendedspectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microbiol. Infect. 14(Suppl. 1):198-202.
8. Graninger, W. 2003. Pivmecillinam-therapy of choice for lower urinary tract infection. Int. J. Antimicrob. Agents 22:S73-S78.
9. Livermore, D. M., R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, L. Poirel, and N. Woodford. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59:165-174.
10. Machado, E., T. M. Coque, R. Canton, F. Baquero, J. C. Sousa, and L. Peixe. 2006. Dissemination in Portugal of CTX-M-15-, OYA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6′)-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme. Antimicrob. Agents Chemother. 50:3220-3221.
11. Mody, R. M., D. P. Erwin, A. M. Summers, H. A. Carrero, E. B. Selby, A. J. Ewell, and K. A. Moran. 2007. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann. Clin. Microbiol. Antimicrob. 6:6.
12. Morosini, M.-I., M. Garcia-Castillo, T. M. Coque, A. Valverde, A. Novais, E. Loza, F. Baquero, and R. Canton. 2006. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50:2695-2699.
13. Nicolle, L. E., and M. R. Mulvey. 2007. Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand. J. Infect. Dis. 39:748-749.
14. Paterson, D. L. 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Med. 119:S20-S28.
15. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
16. Perez, F., A. Endimiani, K. M. Hujer, and R. A. Bonomo. 2007. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7:459-469.
17. Schito, G. C. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22:S79-S83.
18. Schito, G. C., K. G. Naber, H. Botto, J. Palou, T. Mazzei, L. Gualco, and A. Marchese. 2009. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 34:407-413.
19. Schwaber, M. J., S. Navon-Venezia, D. Schwartz, and Y. Carmeli. 2005. High levels of antimicrobial coresistance among extended-spectrum-beta- lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 49:2137-2139.
20. Tamayo, J., B. Orden, J. Cacho, J. Cuadros, J. L. Gomez-Garces, and J. I. Alos. 2007. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid. Rev. Esp. Quimioter. 20:334-338.
21. Turner, P. J. 2005. Extended-spectrum beta-lactamases. Clin. Infect. Dis. 41:S273-S275.
22. Wexler, H. M. 2004. In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. 53:11-21.